Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

Introduction: Although driver gene mutations have been believed to be mutually exclusive, some patients with NSCLC and concomitant EGFR mutations and EML4-ALK rearrangements have been reported. In this study, we reported a case of a patient with lung cancer who harbored both EGFR mutation and the EM...

Full description

Bibliographic Details
Main Authors: Ming-Hung Huang, PhD, Jih-Hsiang Lee, MD, Pei-Shan Hung, PhD, James Chih-Hsin Yang, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR
EML4-ALK
Lung cancer
EGFR-TKI
ALK inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001291

Similar Items

Similar Items